TrialNature communications2026

Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial.

Wenjun Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.